Chemical and pharmacological chaperones as new therapeutic agents. - Test2 - elhamkhani - TriplyDB

Chemical and pharmacological chaperones as new therapeutic agents.

Chemical and pharmacological chaperones as new therapeutic agents.

http://www.wikidata.org/entity/Q36863386

about

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.Newborn screening.Chaperoning G protein-coupled receptors: from cell biology to therapeutics Ipsen 5i is a Novel Potent Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants.Role of ER stress in ventricular contractile dysfunction in type 2 diabetes Naturally occurring osmolytes modulate the nanomechanical properties of polycystic kidney disease domains Phenylalanine hydroxylase misfolding and pharmacological chaperones.Emergent properties of proteostasis in managing cystic fibrosis.Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type.Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.Knitting and untying the protein network: modulation of protein ensembles as a therapeutic strategy.Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease.Endoplasmic reticulum stress in obesity and obesity-related disorders: An expanded view.Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis Chemical conjugation of DeltaF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions.Rational stabilization of complex proteins: a divide and combine approach.What are pharmacological chaperones and why are they interesting?Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension.

P2860

Q21202879-9BCD8E8A-45E1-4BBF-98C1-3E922E44FFD5 Q26992276-D448CCA9-2D70-443B-8B83-7611D7DBB6EF Q33636300-404AE3EC-59A9-4FDB-A049-E26054C4D2F6 Q33718824-6FE02910-F430-428C-B8CE-0862E194E392 Q33868506-3ADD7F05-BB29-4A44-967A-C12DD955F50D Q33927508-B9B6C83D-D7B0-4238-9042-F1BADD6A5CA7 Q33997482-5063D54E-0A05-4140-B7DB-C1176C7DE551 Q34328371-7D74B60A-D8D6-4256-915D-E390D20370DE Q34352256-958E4757-D8B5-4487-BD88-97CB3BCD0E47 Q34556955-0BE7F363-7CCD-4152-B700-01E1792E2393 Q34576386-C0F6B5ED-89DF-4D45-B43A-4401F1BB0926 Q35606973-C531B95A-83D7-41D6-B07B-F79EA7062C5E Q35758335-844441B4-272C-4E16-A8FD-066F577C5BCA Q36740296-2BC0005E-58B6-4A07-BF79-F40FD17C1836 Q36784566-2E6504D9-5F73-42AD-A88E-5BC64EE3593F Q36954679-BD527C19-2D70-4A11-8389-AC241DBF350B Q37060996-589B63F7-7005-4FFE-BFF9-9040AC0346A8 Q37111958-72A1CBAF-80C4-4700-935D-A1A5A8EE8A8E Q37351126-1AD7E8E6-72ED-4A63-8F8C-022360A0C52F Q37383647-03472F52-2293-4008-8BEE-2408D38F1B75 Q38193225-4D5A68D7-0E3F-4D20-B4B4-D02FEE316267 Q38923148-29D758B0-9DC0-4793-9ADC-093035575478 Q39828462-105790F1-4BD2-4F9D-A3C4-5CC5D4726AC7 Q39976627-60BE70EB-CC64-4F7A-A900-55A461A8D41F Q41997423-9FE1EA3D-F088-4460-B2E0-2B864B0B1F26 Q42635564-825ADBE7-E1B7-48C0-BD1C-C427CAA4F3DB Q50014672-98F05319-91DD-43F9-82E9-5AD7214212E8 Q54370056-A6861C25-CFC1-4875-9103-B4ABB7CD62AC

P2860

Chemical and pharmacological chaperones as new therapeutic agents.

http://www.wikidata.org/entity/Q36863386

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Chemical and pharmacological chaperones as new therapeutic agents.

@en

type

label

Chemical and pharmacological chaperones as new therapeutic agents.

@en

prefLabel

Chemical and pharmacological chaperones as new therapeutic agents.

@en

P1433

Q36863386-24AA1EBB-5C08-4E28-B122-82192675B476

P1476

Q36863386-66183CA8-3F62-48AE-B73A-FA0C702AFA06

P2093

Q36863386-FB831733-2B92-4235-90E8-8835A3AB4D4C

Q36863386-FCCC880A-3B34-4B14-9213-453AF7F9F856

P2860

Q36863386-0DAFA9BE-F309-41C5-8326-8A28C22EB50E

Q36863386-143604BA-FE48-488C-80F9-D7AAE35DFAE9

Q36863386-171654B6-D713-4A21-B231-9E69EC871893

Q36863386-19A47D1C-E8C7-4618-9A2F-308BA5E510C2

Q36863386-1A1CF922-FB9D-48ED-AE28-A3415F4E7114

Q36863386-1C73C55B-F876-4348-AE6D-AFA0C5C6C5C4

Q36863386-1F851163-C602-483F-AB93-3B6E236981E4

Q36863386-21114B0D-0F06-4BFA-9FB1-76FEE67A0C30

Q36863386-22BDA787-C468-465A-A161-40D66BEA73DA

Q36863386-2A0351F3-5DE0-428E-86FF-E7A5ACB95C4A

P304

Q36863386-D78B2BC2-BE3D-4775-9B16-6E39DE81EE6F

P31

Q36863386-A90FA224-B0FA-40F3-926D-513726BB3852

P356

Q36863386-8DB034FB-2F93-4006-9670-19EC04AE7E29

P433

Q36863386-1BD4A559-A78A-4417-B6C9-3D50138914A9

P478

Q36863386-F192CD49-22FD-4B7E-BC50-7A2D7CD35B15

P577

Q36863386-C3BB1587-8F65-4AEA-9FB0-0FBBDBB90A56

P698

Q36863386-E2CEC204-F801-4B29-B830-498756879944

P921

Q36863386-BF013E16-2B5A-46B8-A701-231384D552A9

P356

S1462399407000361

P1433

Expert Reviews in Molecular Medicine

P1476

Chemical and pharmacological chaperones as new therapeutic agents.

@en

P2093

David M Clarke

http://www.w3.org/2001/XMLSchema#string

Tip W Loo

http://www.w3.org/2001/XMLSchema#string

P2860

Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis

GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria

Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease

Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Cystic fibrosis

Predicting the effects of amino acid substitutions on protein function

Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress

P304

1-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1462399407000361

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17597553

http://www.w3.org/2001/XMLSchema#string

P921

molecular chaperones